Neuronetics' NeuroStar Advanced Therapy cleared by FDA for treating adolescent depression.

Neuronetics shares increased 15% after the FDA cleared their NeuroStar Advanced Therapy as an adjunct for treating major depressive disorder in adolescents aged 15-21. This is the first FDA-cleared transcranial magnetic stimulation treatment for this age group. The FDA decision is partly based on data from NeuroStar's TrakStar platform, showing 78% of adolescents achieved meaningful improvement in their depression severity.